Evidence map›Paper›PMID 39264518›Full record

ArticleJournal of clinical immunology2024

Non-Skewed X-inactivation Results in NF-κB Essential Modulator (NEMO) Δ-exon 5-autoinflammatory Syndrome (NEMO-NDAS) in a Female with Incontinentia Pigmenti.

Jessica Eigemann, Ales Janda, Catharina Schuetz, Min Ae Lee-Kirsch, Ansgar Schulz, Manfred Hoenig, Ingrid Furlan, Eva-Maria Jacobsen, Julia Zinngrebe, Sarah Peters and 11 more

Abstract readCase Reports
In one paragraph

Article in Journal of clinical immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jessica Eigemann *Master's Program of Molecular Medicine, Medical Faculty of Ulm University, Ulm, Germany.
Ales Janda *Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.
Catharina SchuetzDepartment of Pediatrics, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Min Ae Lee-KirschDepartment of Pediatrics, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Ansgar SchulzDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.
Manfred HoenigDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.
Ingrid FurlanDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.
Eva-Maria JacobsenDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.
Julia ZinngrebeDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.
Sarah PetersDepartment of Clinical Chemistry, Ulm University Medical Center, Ulm, Germany.
Cosima DrewesInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.
Reiner SiebertGerman Center for Child and Adolescent Health (DZKJ), Partner Site Ulm, Ulm, Germany.
Eva-Maria RumpInstitute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Wuerttemberg - Hessen, Ulm, Germany.
Marita FührerInstitute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Wuerttemberg - Hessen, Ulm, Germany.
Myriam LorenzInstitute for Transfusion Medicine, University of Ulm, Ulm, Germany.
Ulrich PannickeInstitute for Transfusion Medicine, University of Ulm, Ulm, Germany.
Uwe KölschDepartment of Immunology, Labor Berlin - Charité Vivantes GmbH, Berlin, Germany.
Klaus-Michael DebatinDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.
Horst von BernuthDepartment of Immunology, Labor Berlin - Charité Vivantes GmbH, Berlin, Germany.
Klaus SchwarzGerman Center for Child and Adolescent Health (DZKJ), Partner Site Ulm, Ulm, Germany.
Kerstin FelgentreffDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany. kerstin.felgentreff@uniklinik-ulm.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGenetic hypomorphic defects in X chromosomal IKBKG coding for the NF-κB essential modulator (NEMO) lead to ectodermal dysplasia and immunodeficiency in males and the skin disorder incontinentia pigmenti (IP) in females, respectively. NF-κB essential modulator (NEMO) Δ-exon 5-autoinflammatory syndrome (NEMO-NDAS) is a systemic autoinflammatory disease caused by alternative splicing and increased proportion of NEMO-Δex5. We investigated a female carrier presenting with IP and NEMO-NDAS due to non-skewed X-inactivation.

methodsIKBKG transcripts were quantified in peripheral blood mononuclear cells isolated from the patient, her mother, and healthy controls using RT-PCR and nanopore sequencing. Corresponding proteins were analyzed by western blotting and flow cytometry. Besides toll-like receptor (TLR) and tumor necrosis factor (TNF) signaling, the interferon signature, cytokine production and X-inactivation status were investigated.

resultsIP and autoinflammation with recurrent fever, oral ulcers, hepatitis, and neutropenia, but no immunodeficiency was observed in a female patient. Besides moderately reduced NEMO signaling function, type I interferonopathy, and elevated IL-18 and CXCL10 were found. She and her mother both carried the heterozygous variant c.613 C > T p.(Gln205*) in exon 5 of IKBKG previously reported in NEMO-deficient patients. However, X-inactivation was skewed in the mother, but not in the patient. Alternative splicing led to increased ratios of NEMO-Dex5 over full-length protein in peripheral blood cell subsets causing autoinflammation. Clinical symptoms partially resolved under treatment with TNF inhibitors.

conclusionNon-skewed X-inactivation can lead to NEMO-NDAS in females with IP carrying hypomorphic IKBKG variants due to alternative splicing and increased proportions of NEMO-∆ex5.

Indexed as

ExonsI-kappa B KinaseIncontinentia PigmentiX Chromosome InactivationAdultAlternative SplicingCytokinesFemaleHereditary Autoinflammatory DiseasesHumansMutationSignal TransductionCytokinesI-kappa B KinaseIKBKG protein, humanAutoinflammationImmunodeficiencyIncontinentia pigmentiNEMONon-skewed X-inactivation

Identifiers

PMID39264518
PMCPMC11393190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.